Sumaila Zaman | Oct 25, 2021, 8:41 PM IST
The Pune-based SII has submitted the final phase 2/3 clinical study report of India with its application for grant of regular market authorization for Covishield.
India.com Lifestyle Staff | Oct 12, 2021, 5:51 PM IST
"After detailed deliberation, the committee recommended for grant of market authorisation of the vaccine for the age group of 2 to 18 years for restricted use in an emergency situation," the expert panel said in a statement.
India.com News Desk | Oct 12, 2021, 2:17 PM IST
Once approved, Covaxin will become the second vaccine to be cleared for use on children.
India.com News Desk | Oct 5, 2021, 8:40 PM IST
Developed by Bharat Biotech in partnership with the National Institute of Virology and ICMR, Covaxin displayed an efficacy of nearly 78 per cent in clinical trials.
India.com News Desk | Oct 3, 2021, 11:43 PM IST
Till now, the company has completed its Phase 2 and Phase 3 trials of Covaxin on children below 18 years of age in September. Presently, the data based on the jab's trials have been handed over to DCGI.
India.com News Desk | Sep 30, 2021, 10:27 AM IST
Bharat Biotech's Covaxin and AstraZeneca and Oxford University's Covishield are the two widely used vaccines in India. Bharat Biotech recently said it submitted all data pertaining to Covaxin to the WHO for EUL and is awaiting feedback from the global health watchdog.
India.com News Desk | Sep 29, 2021, 4:36 PM IST
According to reports, about one crore daily vaccines doses are needed to vaccinate the entire 94 crore population till December 31.
Satakshi Singh | Sep 29, 2021, 9:00 AM IST
According to reports, Hyderabad-based Bharat Biotech will have to answer some more technical questions related to Covaxin, to the World Health Organisation.
India.com News Desk | Sep 27, 2021, 8:34 PM IST
Covaxin cannot be recognised as an accepted vaccine by most countries around the world without WHO's emergency use authorisation.
India.com News Desk | Sep 21, 2021, 4:52 PM IST
According to the Bharat Biotech Chairman, the intranasal vaccine trials are conducted on three cohorts in which one group is administered Covaxin as the first dose and intranasal as the second.
India.com News Desk | Sep 20, 2021, 5:08 PM IST
Union Health Minister Mansukh Mandaviya on Monday informed that India will resume export of vaccines against Coronavirus disease (Covid-19) under the government's 'Vaccine Maitri' initiative
India.com News Desk | Sep 18, 2021, 8:48 AM IST
WHO's approval for the emergency use authorisation (EUA) to COVID-19 vaccine Covaxin, developed by the Hyderabad-based Bharat Biotech, is likely to be delayed till October 5.
English
